Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Combined with TACE and Microwave Ablation for Unresectable HCC
NCT04220944Phase 1Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression Free Survival at 18 months. Started Jan 2020; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04220944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220944.